Publication

Erratum: Intracellular activation of a prostate specific antigen-cleavable doxorubicin prodrug: A key feature toward prodrug-nanomedicine design (Molecular Pharmaceutics (2019) 16:4 (1573-1585) DOI:10.1021/acs.molpharmaceut.8b01257)

Pereira, S. G. T., Hudoklin, S., Kreft, M. E., Kostevsek, N., Stuart, M. C. A. & Al-Jamal, W. T., 3-Aug-2020, In : Molecular pharmaceutics. 17, 8, p. 3149-3149 1 p.

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Copy link to clipboard

Documents

  • Correction

    Final publisher's version, 808 KB, PDF document

    Request copy

DOI

  • Sara G. T. Pereira
  • Samo Hudoklin
  • Mateja Erdani Kreft
  • Nina Kostevsek
  • Marc C. A. Stuart
  • Wafa T. Al-Jamal

In the original document, the chemical structure of the PSA-cleavable peptide on page 1574 was (glutaryl-4-Hyp-AlaSer-Chg-Gln-Ser-Leu-OH). The correct chemical structure is ((MeO2C-C-(CH2)3-CO-4-Hyp-Ala-Ser-Chg-Gln-Ser-Leu-OH). In the original document, the chemical structure of PSAcleavable peptide (Figure 1A) on page 1576 is shown: The correct chemical structure in Figure 1A is shown. (Figure Presented).

Original languageEnglish
Pages (from-to)3149-3149
Number of pages1
JournalMolecular pharmaceutics
Volume17
Issue number8
Publication statusPublished - 3-Aug-2020
Related Publications
  1. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Towards Prodrug-Nanomedicine Design

    Pereira, S. G. T., Hudoklin, S., Kreft, M. E., Kostevsek, N., Stuart, M. C. A. & Al-Jamal, W. T., Apr-2019, In : Molecular pharmaceutics. 16, 4, p. 1573-1585 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (1) »

ID: 132703658